HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager patientINFORMation Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kleefstra, N. Articles by Bilo, H. J.G. Search for Related Content PubMed PubMed Citation Articles by Kleefstra, N. Articles by Bilo, H. J.G. Social Bookmarking                What's this?

Chromium Treatment Has No Effect in Patients With Poorly Controlled, Insulin-Treated Type 2 Diabetes in an Obese Western Population

A randomized, double-blind, placebo-controlled trial

¹ Department of Internal Medicine, Isala Clinics, Weezenlanden Location, Zwolle, the Netherlands
² Department of General Practice, University of Groningen, Groningen, the Netherlands
³ Department of Pharmacology and Pharmaceutical Care, Groningen University Institute for Drug Exploration, Groningen, the Netherlands
⁴ Department of Clinical Pharmacy, Isala Clinics, Weezenlanden Location, Zwolle, the Netherlands
⁵ Department of Internal Medicine, University Hospital Groningen, Groningen, the Netherlands

Address correspondence and reprint requests to Nanne Kleefstra, MD, Department of Internal Medicine, Isala Clinics, Weezenlanden Location, P.O. Box 10500, 8000 GM Zwolle, Netherlands. E-mail: kleefstra{at}langerhans.com

OBJECTIVE—Chromium treatment has been reported to improve glycemic control and insulin sensitivity in specific populations of patients with type 2 diabetes. The aim of this study was to determine the effect of chromium treatment on glycemic control in a Western population of insulin-dependent patients with type 2 diabetes.

RESEARCH DESIGN AND METHODS—In this 6-month double-blind study, patients with an HbA_1c (A1C) >8% and insulin requirements of >50 units/day were randomly assigned to receive treatment with placebo or 500 or 1,000 µg chromium daily in the form of chromium picolinate. The primary efficacy parameter was a change in A1C. Secondary end points were changes in lipid profile, BMI, blood pressure, and insulin requirements.

RESULTS—In this per-protocol analysis (n = 46), the decrease in A1C was approximately equal across the three groups (0.4%). All patients had a BMI >25 kg/m². No differences were found in the secondary end points. We found a weak relationship between an increasing serum chromium concentration and improvement of the lipid profile.

CONCLUSIONS—There is no evidence that high-dose chromium treatment is effective in obese Western patients with type 2 diabetes.

CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

Find additional patient-related information at:

Chromium Has No Benefits for Obese Westerners With Poorly Controlled Type 2 Diabetes

This article has been cited by other articles:

				S. E. Woods, V. Ghodsi, A. Engel, J. Miller, and S. James Serum Chromium and Gestational Diabetes J Am Board Fam Med, March 1, 2008; 21(2): 153 - 157. [Abstract] [Full Text] [PDF]

				American Diabetes Association Nutrition Recommendations and Interventions for Diabetes: A position statement of the American Diabetes Association Diabetes Care, January 1, 2008; 31(Supplement_1): S61 - S78. [Full Text] [PDF]

				E. M. Balk, A. Tatsioni, A. H. Lichtenstein, J. Lau, and A. G. Pittas Effect of Chromium Supplementation on Glucose Metabolism and Lipids: A systematic review of randomized controlled trials Diabetes Care, August 1, 2007; 30(8): 2154 - 2163. [Abstract] [Full Text] [PDF]

				N. Kleefstra, S. T. Houweling, S. J.L. Bakker, S. Verhoeven, R. O.B. Gans, B. Meyboom-de Jong, and H. J.G. Bilo Chromium Treatment Has No Effect in Patients With Type 2 Diabetes in a Western Population: A randomized, double-blind, placebo-controlled trial Diabetes Care, May 1, 2007; 30(5): 1092 - 1096. [Abstract] [Full Text] [PDF]

				American Diabetes Association Nutrition Recommendations and Interventions for Diabetes: A position statement of the American Diabetes Association Diabetes Care, January 1, 2007; 30(suppl_1): S48 - S65. [Full Text] [PDF]

				D. A. Mark Chromium Picolinate Supplementation Attenuates Body Weight Gain and Increases Insulin Sensitivity in Subjects With Type 2 Diabetes: Response to Martin et al. Diabetes Care, December 1, 2006; 29(12): 2764 - 2764. [Full Text] [PDF]

				J. Martin, D. Matthews, and W. T. Cefalu Chromium Picolinate Supplementation Attenuates Body Weight Gain and Increases Insulin Sensitivity in Subjects With Type 2 Diabetes: Response to Mark Diabetes Care, December 1, 2006; 29(12): 2764 - 2765. [Full Text] [PDF]

				C. Rink, S. Roy, S. Khanna, T. Rink, D. Bagchi, and C. K. Sen Transcriptome of the subcutaneous adipose tissue in response to oral supplementation of type 2 Leprdb obese diabetic mice with niacin-bound chromium Physiol Genomics, November 21, 2006; 27(3): 370 - 379. [Abstract] [Full Text] [PDF]

				American Diabetes Association Nutrition Recommendations and Interventions for Diabetes-2006: A position statement of the American Diabetes Association. Diabetes Care, September 1, 2006; 29(9): 2140 - 2157. [Full Text] [PDF]

				J. Martin, Z. Q. Wang, X. H. Zhang, D. Wachtel, J. Volaufova, D. E. Matthews, and W. T. Cefalu Chromium Picolinate Supplementation Attenuates Body Weight Gain and Increases Insulin Sensitivity in Subjects With Type 2 Diabetes Diabetes Care, August 1, 2006; 29(8): 1826 - 1832. [Abstract] [Full Text] [PDF]

				J. Hendry Chromium Supplement Controversy Continues DOC News, June 1, 2006; 3(6): 9 - 9. [Full Text] [PDF]